Mygene
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Mygene - overview
Established
2015
Location
Guangzhou, Guangdong, China
Primary Industry
Biotechnology
About
Based in Guangzhou, China, and established in 2015, Mygene operates as a medical solution provider that offers tumor detection services for users through utilizing gene-sequencing technology, with a third-party medical testing laboratory in Guangzhou. In December 2019, it reached an IVD partnership agreement with Illumina. In April 2017, the Silicon Valley R&D Center was completed. The Chief Scientist Officer, Chunlin Wang, graduated from Stanford University.
The company's genetic testing services can be categorized into lung cancer, colorectal cancer, breast cancer, gastrointestinal mesenchymal tumor, parenchymal tumor, childhood tumor, and prostate cancer.
Current Investors
Shenzhen Capital Real Estate Fund, CASH Capital, Greatwall Fund
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment
Website
www.maijinggene.com
Company Stage
Series C
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.